Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198484 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Vitrase as a Spreading Agent
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 108
- Enrollment target
NCT00198484 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 108 participants.
The verdict
NCT00198484, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 108 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Vitrase (hyaluronidase for injection) is effective as a spreading agent for other injected drugs prior to ocular surgery
Interventions
- DRUG Vitrase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00198484
The ClinicalTrials.gov registry entry for NCT00198484 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vitrase is the first listed.
NCT00198484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00198484 about?
NCT00198484 is a clinical study titled "Evaluation of Vitrase as a Spreading Agent". The purpose of this study is to determine whether Vitrase (hyaluronidase for injection) is effective as a spreading agent for other injected drugs prior to ocular surgery
What is the current status of trial NCT00198484?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 108 participants. The study started on 2004-10. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00198484?
The interventions under investigation include: Vitrase (DRUG).
Who is sponsoring clinical trial NCT00198484?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.